WAidid suggests the article Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults, published on Vaccine on August 2015 and available online from July 15.

SUMMARY:
Adolescents and young adults constitute a high-risk age group for invasive meningococcocal diseases (IMD) and the majority of cases could be vaccine-preventable. The incidence of IMD due to specific serogroups, including serogroup B, varies over geographic regions and over time. Despite rapid, high quality medical care, meningococcal disease can be fatal and is associated with long-term sequelae. In adolescents, increased endemic disease rates and outbreak potential are likely associated with social behaviors putting individuals at risk for carriage acquisition and may explain regional and temporal variations in epidemiology. A protein-based, multi-component MenB vaccine (4CMenB) is currently licensed for use in 37 countries including EU/EEA countries, Australia, Canada, Chile, Colombia, Uruguay, and theUS. In this article the authors review the most recent clinical trial data with 4CMenB with a focus on adolescents and young adults. The vaccine appears to have an acceptable safety profile and is well-tolerated in adolescents and young adults while providing robust, persistent levels of bactericidal antibodies considered protective for each of the four antigenic components of the vaccine. With the recent availability of thisvaccine, health care providers have the first comprehensive opportunity to control meningococcal disease, a highly disruptive public health problem with a disproportionate impact on adolescents and young adults.

AUTHORS: Terry Nolan, Miguel O’Ryan, James Wassil, Véronique Abitbol, Peter Dull

To read the article, click here.